Company / PP&E (Net)
Vanda Pharmaceuticals Inc. PP&E (Net) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$2.2M
FY2025
5-year range
$2.0M / $3.1M
FY2021-FY2025
Trend
+5.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
PP&E (Net) has fluctuated over the past 10 years, ranging from $2M in FY2023 to $5M in FY2017.
Based on SEC 10-K filings.
$2M in FY2025 with a 5-year CAGR of -11.5%.
Improved from $2M to $2M over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -4.4%
- 5-Year CAGR
- -11.5%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -11.5%, indicating a declining trend.
- In FY2025, pp&e (net) increased 5.4% year-over-year.
- Peak pp&e (net) was recorded in FY2017.
- Lowest pp&e (net) in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.2M | +5.4% |
| FY2024 | $2.1M | +4.7% |
| FY2023 | $2.0M | -20.8% |
| FY2022 | $2.6M | -17.3% |
| FY2021 | $3.1M | -24.7% |
| FY2020 | $4.1M | +7.0% |
| FY2019 | $3.9M | -12.5% |
| FY2018 | $4.4M | -16.8% |
| FY2017 | $5.3M | +5.8% |
| FY2016 | $5.0M | +9.7% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026